Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain

被引:240
作者
Zhang, QZ [1 ]
Jiang, XG [1 ]
Jiang, WM [1 ]
Lu, W [1 ]
Su, LN [1 ]
Shi, ZQ [1 ]
机构
[1] Fudan Univ, Dept Pharmaceut, Sch Pharm, Shanghai 200032, Peoples R China
关键词
nimodipine; microemulsion; intranasal delivery; solubilization; olfactory pathway; brain targeting;
D O I
10.1016/j.ijpharm.2004.01.039
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to improve the solubility and enhance the brain uptake of nimodipine (NM) in an o/w microemulsion, which was suitable for intranasal delivery. Three microemulsion systems stabilized by the nonionic surfactants either Cremophor RH 40 or Labrasol, and containing a variety of oils, namely isopropyl myristate, Labrafil M 1944CS and Maisine 35-1 were developed and characterized. The nasal absorption of NM from microemulsion formulation was investigated in rats. The optimal microemulsion formulation consisted of 8% Labratil M 1944CS, 30% Cremophor RH 40/ethanol (3:1) and water, with a maximum solubility of NM up to 6.4 mg/ml, droplet size of 30.3 +/- 5.3 nm, and no ciliotoxicity. After a single intranasal administration of this preparation at a dose of 2 mg/kg, the plasma concentration peaked at 1 h and the absolute bioavailability was about 32%. The uptake of NM in the olfactory bulb from the nasal route was three folds, compared with intravenous (i.v.) injection. The ratios of AUC in brain tissues and cerebrospinal fluid to that in plasma obtained after nasal administration were significantly higher than those after i.v. administration. These results suggest that the microemulsion system is a promising approach for intranasal delivery of NM for the treatment and prevention of neurodegenerative diseases. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:85 / 96
页数:12
相关论文
共 26 条
[1]   Effects of physicochemical properties and other factors on systemic nasal drug delivery [J].
Behl, CR ;
Pimplaskar, HK ;
Sileno, AP ;
deMeireles, J ;
Romeo, VD .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :89-116
[2]   Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia [J].
Blardi, P ;
Urso, R ;
de Lalla, A ;
Volpi, L ;
Di Perri, T ;
Auteri, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :556-561
[3]  
Chou KJ, 1997, BIOPHARM DRUG DISPOS, V18, P335, DOI 10.1002/(SICI)1099-081X(199705)18:4<335::AID-BDD22>3.0.CO
[4]  
2-W
[5]  
Chow HHS, 1999, J PHARM SCI, V88, P754
[6]   Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats [J].
Dahlin, M ;
Björk, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 195 (1-2) :197-205
[7]   Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A [J].
Gao, ZG ;
Choi, HG ;
Shin, HJ ;
Park, KM ;
Lim, SJ ;
Hwang, KJ ;
Kim, CK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 161 (01) :75-86
[8]   CALCIUM-CHANNEL BLOCKERS IN THE TREATMENT OF MIGRAINE [J].
GELMERS, HJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1985, 55 (03) :B139-B143
[9]  
GLERTLOVA M, 1992, PHARMAZIE, V47, P861
[10]   Transport of drugs from the nasal cavity to the central nervous system [J].
Illum, L .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 (01) :1-18